Patent ID: 9205086
Filing Date: 2015-12-08
Classification: A61K,A61P

Abstract:
1. A method of treating non small cell lung cancer in a mammal, comprising administering to the mammal an effective amount of an compound, which is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of an EGFR inhibitor, wherein, the EGFR inhibitor is erlotinib and the effective amount of the compound and the effective amount of the EGFR inhibitor together results in a synergistic effect against the non-small cell lung cancer.